Antisense Oligonucleotides in the Treatment of Cerebral Gliomas. Review of Concerning Patents

Author(s): Gerardo Caruso, Maria Caffo

Journal Name: Recent Patents on CNS Drug Discovery (Discontinued)

Volume 9 , Issue 1 , 2014


Gliomas are the most common and malignant primary brain tumors in the adult population. Despite the intensive research on cancer pathology, real mechanisms concerning glioma progression are not completely understood. The prognosis in patients affected by malignant gliomas is still very unfavorable. Recent genomic analyses have revealed patterns of molecular changes within tumor subclasses that harbor distinct underlying biology, clinical prognosis, and pathogenic routes. So, novel treatments will have to be able to interfere at different molecular levels in gliomagenesis minimizing the toxicity. In particular, antisense oligonucleotides are able to inhibit expression of specific genes by interfering with transcription or, more usually, with translation.

In this review, we will focus on mechanisms of antisense oligonucleotides reporting clinical and experimental studies. We will also report a large number of patents which adopt the antisense oligonucleotides as potential therapeutic approach in gliomas treatment.

Keywords: Angiogenesis, antisense oligonucleotides, apoptosis, gliomas.

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 28 April, 2014
Page: [2 - 12]
Pages: 11
DOI: 10.2174/1574889809666140307113439

Article Metrics

PDF: 47